Concepedia

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley, Ben Van Calster, Sang‐Yoon Park, Josep M. del Campo, Werner Meier, Aristotelis Bamias, Nicoletta Colombo, Robert M. Wenham,

The Lancet Oncology · 2019 · 86 citations · 22 references

DOIFull text

Open access

Concepts

References

22

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

David Cella, David S. Tulsky, Geoffrey V. Gray et al. · Journal of Clinical Oncology · 1993 · 6K citations

, , +15

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text

, , +11

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Timothy Perren, Ann Marie Swart, Jacobus Pfisterer et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text

, , +11

Checking the Cox model with cumulative sums of martingale-based residuals

D. Y. Lin, L. J. Wei, Z. Ying · Biometrika · 1993 · 1.4K citations

, , +16